Rhythm Pharmaceuticals RYTM 深 沪
等待开盘 10-22 09:30:00 美东时间
107.59
-4.800
-4.27%
华盛通- 最 高113.07
- 今 开112.31
- 成交量 16.51万股
- 最 低 107.58
- 昨 收 112.39
- 总市值 68.45亿
- 52周最高 113.91
- 市盈率 静 --
- 换手率 0.26%
- 52周最低 45.905
- 委 比 -21.89%
- 总股本 6362.15万
- 历史最高 113.91
- 量 比 0.59
- 振 幅 4.88%
- 历史最低 3.04
- 每 手 1
- 风险率 18.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
美股大行评级 | Needham上调台积电目标价升至360美元！美国银行、摩根士丹利分别获多家机构上调目标价
今日重点评级关注：Rosenblatt：维持HIVE Digital Technologies"买入"评级，目标价从5美元升至10美元；摩根大通：维持Array Technologies"超配"评级，目标价从13美元升至15美元
10-17 09:58
Morgan Stanley Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $129
Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $122 to $129.
10-17 02:01
美股大行评级 | 潜在涨幅207.38%！GoldMining获HC Wainwright升目标价至3.75美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持GoldMining"买入"评级，目标价从3.25美元升至3.75美元；摩根士丹利：维持Crinetics Pharmaceuticals"超配"评级，目标价从65美元升至77美元
09-30 14:16
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
美股大行评级 | 217美元！花旗上调阿里巴巴目标价；多家机构集体上调麦克森、美光科技等目标价
今日重点评级关注：Ascendiant Capital：维持Maison Solutions"买入"评级，目标价从4美元升至4.25美元；瑞穗：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至56美元
09-25 09:52
Goldman Sachs Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $138
Goldman Sachs analyst Corinne Jenkins maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $105 to $138.
09-25 02:01
Agrify Corporation to Change Its Name to RYTHM, Inc. Following Brand Portfolio Acquisition
Agrify Corporation acquired the brand portfolio from Green Thumb Industries for $50 million via a convertible note, including RYTHM, Dogwalkers, and Beboe. They also entered a licensing agreement. Agrify will rebrand as RYTHM Inc and trade under "RYM" on Nasdaq from Sept. 2, 2025. The acquisition aims to position the company for growth in licensing revenue and THC product sales. The transaction results in ~2.0 million outstanding shares, 7.6 mill...
08-27 20:20
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
Dr. David Meeker, CEO of Rhythm Pharmaceuticals, will participate in fireside chats at the Wells Fargo Healthcare Conference on September 3, 2025, and the Morgan Stanley Global Healthcare Conference on September 9, 2025. Rhythm is a biopharmaceutical company focused on rare neuroendocrine diseases, with IMCIVREE® (setmelanotide) approved for obesity treatment in patients with BBS or specific genetic deficiencies. The drug is available in the U.S....
08-27 20:01
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced the U.S. FDA has accepted its supplemental New Drug Application (sNDA) for setmelanotide to treat acquired hypothalamic obesity, granting Priority Review with a PDUFA goal date of December 20, 2025. The European Medicines Agency (EMA) also validated the Type II variation submission for the same indication. The company will host a commercial readiness event for investors and analysts on September 24, 2025, in Bosto...
08-20 20:01
